



# 3Q 2021 Financial results

## 3Q 2021

Worldwide sales  
**\$13.2 billion**

GAAP EPS  
**\$1.80**

Non-GAAP EPS  
**\$1.75**

## 2021 Continuing operations financial outlook

Expects full-year 2021 sales growth of 14% to 15%; raises and narrows estimated full-year 2021 revenue range to be between \$47.4 billion and \$47.9 billion, including a positive impact from foreign exchange of approximately 1.5%

Raises and narrows full-year 2021 GAAP EPS to be between \$4.71 and \$4.76; raises and narrows full-year 2021 Non-GAAP EPS to be between \$5.65 and \$5.70, including a positive impact from foreign exchange of approximately 2%

## Key growth drivers

### Oncology


**KEYTRUDA®**  
(pembrolizumab) injection 100 mg

Higher sales and continued uptake

 +  | **Lynparza®**  
olaparib tablets 150 mg

 +  | **LENVIMA®**  
(lenvatinib) capsules 10 mg and 4 mg

### Vaccines

  
**GARDASIL®**  
[Human Papillomavirus Quadrivalent  
(Types 6, 11, 16, and 18) Vaccine, Recombinant]

+

  
**GARDASIL® 9**  
[Human Papillomavirus  
9-valent Vaccine, Recombinant]

Growth driven by higher demand in China, as well as increased supply and ability to reallocate

### Hospital Acute Care

**bridion®**  
(sugammadex) injection 100 mg/mL\*

Higher demand globally and pandemic recovery

### Animal Health

 **MSD**  
Animal Health

Higher global demand in companion animal and livestock products, including Animal Health Intelligence products



“MSD delivered another strong quarter with positive momentum across our business and meaningful progress across our pipeline. Our teams continued to excel as we focus on evolving our operations, while driving innovations in our labs that exemplify the best of MSD science.

We achieved notable clinical milestones in the key areas of oncology and COVID-19, including positive Phase 3 results for molnupiravir. We recently announced our proposed acquisition of Acceleron, which will strengthen our cardiovascular portfolio with complementary, cutting-edge science and an exciting late-stage candidate.

Looking ahead, we remain focused on building more momentum, delivering on our mission of saving and improving lives and continuing to expand our portfolio and pipeline for long-term success and sustainable value creation.”

**Rob Davis**  
CEO and President